Dianthus Therapeutics, Inc. /DE/ Auditor
The independent registered public accounting firm that signed the audit report in each annual report on Form 10-K, newest first. PCAOB firm ID and the internal-control attestation are as tagged on the cover from fiscal 2021; earlier rows come from the signed report text.
- 2026-03-09: Fiscal year end 2025-12-31; Auditor Deloitte & Touche LLP; PCAOB firm ID 34; Location Morristown, New Jersey.
- 2025-03-11: Fiscal year end 2024-12-31; Auditor Deloitte & Touche LLP; PCAOB firm ID 34; Location Morristown, New Jersey.
- 2024-03-21: Fiscal year end 2023-12-31; Auditor Deloitte & Touche LLP; PCAOB firm ID 34; Location Morristown, New Jersey.
- 2023-05-01: Fiscal year end 2022-12-31; Auditor KPMG LLP; PCAOB firm ID 185; Location Boston, Massachusetts.
| Filed | Fiscal year end | Auditor | PCAOB firm ID | Location | Internal-control attestation |
|---|
| 2026-03-09 | 2025-12-31 | Deloitte & Touche LLP | 34 | Morristown, New Jersey | No |
|---|
| 2025-03-11 | 2024-12-31 | Deloitte & Touche LLP | 34 | Morristown, New Jersey | No |
|---|
| 2024-03-21 | 2023-12-31 | Deloitte & Touche LLP | 34 | Morristown, New Jersey | No |
|---|
| 2023-05-01 | 2022-12-31 | KPMG LLP | 185 | Boston, Massachusetts | No |
|---|
| 2023-03-23 | 2022-12-31 | KPMG LLP | 185 | Boston, Massachusetts | No |
|---|
| 2022-03-08 | 2021-12-31 | KPMG LLP | 185 | Boston, Massachusetts | No |
|---|
| 2021-03-03 | 2020-12-31 | KPMG LLP | | Boston, Massachusetts | No |
|---|
| 2020-03-03 | 2019-12-31 | KPMG LLP | | Boston, Massachusetts | |
|---|
| 2019-03-19 | 2018-12-31 | KPMG LLP | | Cambridge, Massachusetts | |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
|---|
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
|---|
| Veradermics, Inc (MANE) | United States | $4.839B | |
|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
|---|
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
|---|
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
|---|